Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 09.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 08.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 07.12.22
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
eqs_en 
0 06.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 06.12.22
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
EQS-News: Gerresheimer AG: Gerresheimer to expand significantly in High Value Solutions and further accelerates its sustainable profitable growth
eqs_en 
0 06.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 05.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 02.12.22
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 01.12.22
Maple Heights Behavioral Health Hosts Ceremony Celebrating Opening: https://mms.businesswire.com/media/20221130005962/en/1651938/5/MH_ribbon_tying_image.jpg
Maple Heights Behavioral Health Hosts Ceremony Celebrating Opening


Maple Heights Behavioral Health, a new hospital at 3955 W. Washington Center Rd., held a ribbon-tying ceremony Wednesday to mark its opening and celebrate the joint venture between Acadia

BusinessWire_EN 
0 01.12.22
EQS-News: MorphoSys AG: Financial Calendar 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG: Financial Calendar 2023
eqs_en 
0 28.11.22
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants: https://mms.businesswire.com/media/20221127005124/en/1647007/5/Almirall_HQ_in_Barcelona.jpg
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants


Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA

BusinessWire_EN 
0 28.11.22
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
eqs_en 
0 16.11.22
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada: https://mms.businesswire.com/media/20221115005460/en/1637032/5/Canada_office_opening.jpg
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada


Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology company working to extend survival

BusinessWire_EN 
0 15.11.22
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio
EQS-Adhoc: GN Store Nord A/S: GN announces appointment of new CEO in GN Audio
eqs_en 
0 11.11.22
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
eqs_en 
0 10.11.22
EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
EQS-News: RHÖN-KLINIKUM AG closes first nine months of 2022 with revenue surplus
eqs_en 
0 10.11.22
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
eqs_en 
0 09.11.22
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
eqs_en 
0 03.11.22
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
eqs_en 
0 03.11.22
EQS-News: Evotec completes acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec completes acquisition of Central Glass Germany
EQS-News: Evotec completes acquisition of Central Glass Germany
eqs_en 
0 03.11.22
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022
EQS-Adhoc: GN Store Nord A/S: GN Store Nord’s Audio division revises financial guidance for 2022
eqs_en 
0 02.11.22
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
eqs_en 
0 02.11.22